Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BND 22 (Primary) ; Cetuximab (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Liver cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Biond Biologics

Most Recent Events

  • 29 Apr 2025 Planned End Date changed from 24 Feb 2027 to 30 Jun 2025.
  • 29 Apr 2025 Planned primary completion date changed from 24 Feb 2027 to 30 Jun 2025.
  • 03 Mar 2025 According to a Biond Biologics media release, company announced that it would regain full rights to BND-22 (SAR444881) from Sanofi. Sanofi is returning the rights of BND-22 as part of their broader R&D prioritization to focus on programs that support the company's strategy. Biond and Sanofi, are working together to complete full transfer of the BND-22 program to Biond. As part of the agreement, Biond will regain full rights to BND-22, including access to the clinical data generated by Sanofi

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top